A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) who are inadequate responders to ursodeoxycholic acid (UDCA)

  1. Lookup NU author(s)
  2. Professor David Jones
Author(s)Jones D, Galambos MR, Swain MG, Doerffel Y, Steinberg A, Varga M, Choi YJ, Martin R, McWherter C, Chera H, Boudes P, Hirschfield GM
Editor(s)
Publication type Conference Proceedings (inc. Abstract)
Conference NameThe Liver Meeting AASLD 2016
Conference LocationBoston MA
Year of Conference2016
Source Publication Date
Volume64
Pages1123A-1124A
Series TitleHepatology
0270-9139
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
PublisherJohn Wiley & Sons, Inc.
URLhttps://doi.org/10.1002/hep.28909
DOI10.1002/hep.28909
Actions    Link to this publication
Share